Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity
Authors:
Open Access
- 26 July 2022
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (11) , 5294-5303
Abstract
The avidity (binding strength) of IgG directed towards the receptor‐binding domain (RBD) of spike protein has been recognized as a central marker in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serology. It seems to be linked to increased infection‐neutralization potential and therefore might indicate protective immunity. Using a prototype line assay based on the established recomLine SARS‐CoV‐2 assay, supplemented with RBD of the delta and the omicron variant, differential avidity determination of IgG directed towards RBD of wild‐type (WT) SARS‐CoV‐2 and distinct variants was possible within one assay. Our data confirm that natural SARS‐CoV‐2 infection or one vaccination step lead to low avidity IgG, whereas further vaccination steps gradually increase avidity to high values. High avidity is not reached by infection alone. After infection with WT SARS‐CoV‐2 or vaccination based on mRNA WT, the avidity of cross‐reacting IgG directed towards RBD of the delta variant only showed marginal differences compared to IgG directed towards RBD WT. In contrast, the avidity of IgG cross‐reacting with RBD of the omicron variant was always much lower than for IgG RBD WT, except after the third vaccination step. Therefore, parallel avidity testing of RBD WT and omicron seems to be mandatory for a significant assessment of protective immunity towards SARS‐CoV‐2.Keywords
This publication has 49 references indexed in Scilit:
- The variability of the serological response to SARS‐corona virus‐2: Potential resolution of ambiguity through determination of avidity (functional affinity)Journal of Medical Virology, 2020
- Diagnostic accuracy of six commercial SARS-CoV-2 IgG/total antibody assays and identification of SARS-CoV-2 neutralizing antibodies in convalescent seramedRxiv, 2020
- Direct observation of repeated infections with endemic coronavirusesmedRxiv, 2020
- Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapyInternational Journal of Infectious Diseases, 2010
- Mechanism and Regulation of Class Switch RecombinationAnnual Review of Immunology, 2008
- Clinical utility of avidity assaysExpert Opinion on Medical Diagnostics, 2007
- Changes in Avidity and Level of Immunoglobulin G Antibodies to Mycobacterium tuberculosis in Sera of Patients Undergoing Treatment for Pulmonary TuberculosisClinical and Vaccine Immunology, 2003
- Avidity of IgG in serodiagnosis of infectious diseasesReviews and Research in Medical Microbiology, 1993
- Kinetic maturation of an immune responseNature, 1991
- Variations in Affinities of Antibodies during the Immune Response*Biochemistry, 1964